Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo may prevent dangerous ovarian condition in fertility patients

NCT ID NCT07568886

Prevention Sponsor: Al-Nahrain University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving albumin and furosemide right after egg retrieval can prevent severe ovarian hyperstimulation syndrome (OHSS) in women at high risk during ICSI. OHSS can cause swelling, fluid buildup, and sometimes hospitalization. The trial involved 200 women and compared the drug combination to standard care. The goal is to find a simple way to make fertility treatments safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albumin and furosemide
What this could lead to
If effective, this combination could become a standard preventive treatment for ovarian hyperstimulation syndrome in high-risk women undergoing fertility treatments.
What could go wrong
This is a single completed trial with 200 participants. Results may not apply to all patients, and the combination may not reduce severe cases significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Apr 2019

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- The inclusion criteria were females aged ≤35 years old, previous history of severe OHSS, AMH\> 3.4, antral follicles count ≥22, presence of \>18 follicles with a diameter \>11 mm at any day of the stimulation cycle, serum estradiol ≥3500 pg/ml at day of hCG trigger, and aspiration of \>15 oocytes at day of oocyte pick up. Exclusion Criteria: * Any female who does not meet those criteria were excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian hyper stimulation syndrome (OHSS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian hyperstimulation syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian hyper stimulation syndrome (OHSS)

Contacts and locations

Locations

  • High Institute for Infertility Diagnosis and ART

    Baghdad, Baghdad Governorate, 10006, Iraq